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parameters with p < 0.001. Compared to MMF, reduced-dose of
CsA with everolimus decreased the one-year total direct medical
cost due to major clinical events by HF 1,373,254 and HF
1,387,057 for everolimus 1.5mg and 3.0mg, respectively (see
table) . Adjusted for patient characteristics, the cost savings
become HF 940,380 for everolimus 1.5mg and HF 838,570 for
everolimus 3.0mg. CONCLUSION: The use of reduced-dose
CsA with everolimus 1.5mg in de novo kidney transplant recip-
ients improves transplant outcomes and reduces one-year total
direct medical cost compared to an MMF based strategy.
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OBJECTIVES: To examine the economic impact of extended-
release tolterodine (TOL-ER) versus immediate- (IR) or
extended-release (ER) oxybutynin (OXY) in patients with over-
active bladder (OAB). METHODS: This retrospective cohort
study used the PharMetrics Patient-Centric Database to identify
patients diagnosed with OAB who newly started therapy with
TOL-ER, OXY-IR, or OXY-ER between January 2001 and
December 2002. 12-month pretreatment and follow-up periods
were established from the ﬁrst prescription date. TOL-ER
patients were matched to OXY-IR and OXY-ER patients based
on an estimated propensity score for TOL-ER therapy (i.e., prob-
ability of TOL-ER use based on multiple logistic regression). Use
of OAB pharmaceuticals and related medications; use of outpa-
tient and inpatient services related to OAB, infection, depression,
and other conditions; and all corresponding costs were compiled
for 1 year. Costs were compared using Wilcoxon rank-sum tests,
and total health care costs were validated in a multivariate
context using a generalized linear model. RESULTS: A total of
7257 TOL-ER/OXY-ER (80% female) and 5936 TOL-ER/OXY-
IR (72% female) matched pairs were created (mean age, 54y).
Because of matching, demographic and clinical characteristics
between cohorts were not signiﬁcantly different. Costs for ser-
vices related to OAB, infection, and depression were signiﬁcantly
lower for TOL-ER vs. OXY-ER. Total health care costs were also
signiﬁcantly reduced for TOL-ER (mean [SD], $8303 [$18,802])
vs. OXY-ER ($8862 [$18,864], p = 0.0109). Medication costs
were signiﬁcantly higher for TOL-ER ($2791 [$4997]) than for
OXY-IR ($2204 [$3944], p < 0.0001). However, this increase
was offset by reductions in expenses related to conditions includ-
ing infection and depression. Total costs did not differ signiﬁ-
cantly between TOL-ER and OXY-IR. After adjustment for
between-group differences, costs were signiﬁcantly reduced for
TOL-ER patients versus OXY-ER and OXY-IR (p < 0.01). CON-
CLUSION: Patients with OAB initiating therapy with TOL-ER
incurred lower annual health care costs, including nonpharma-
cologic costs related to OAB, infection, and depression compared
with those receiving OXY-IR or OXY-ER.
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OBJECTIVES: Overactive bladder (OAB) is associated with both
an economic and quality of life burden. Current management
involves antimuscarinic agents. Extended release formulations
are expected to improve treatment compliance and persistence.
This study explored persistence and impact on OAB related co-
morbidities with two therapies: tolterodine extended release
(TER) and oxybutynin immediate release (OIR) compared to no
active drug treatment (NONE) and associated costs across ﬁve
European countries. METHODS: A decision-analytic model esti-
mated costs and outcomes associated with treatment. A large
case-controlled study was used to estimate the percentage of
patients achieving persistent control, deﬁned as patients still on
therapy after six months. Resource use included drug costs,
physician visits, incontinence pads and the cost of urinary tract
and skin infections. The model estimated the cost per patient
achieving persistent control of OAB. Costs were estimated from
the perspective of health service payers over six months. Sensi-
tivity analyses included variation of the resource use frequency
assumptions, cost inputs, and the time horizon of the analysis.
RESULTS: After six months, the proportion of patients achiev-
ing persistent control was 39% on TER and 9% on OIR. Costs
per patient for TER ranged between €349 (Germany) and €772
(Sweden) and between €177 (Germany) and €693 (Sweden) for
OIR. Compared against NONE, the Incremental Cost-Effective-
ness Ratios (ICERs) for TER were much lower than for OIR.
ICERs of TER vs. OIR ranged between €351 (Sweden) and €822
(Spain). Sensitivity analysis highlighted the model’s sensitivity to
the time horizon, physician costs and persistency rates. Differ-
ences in costs largely reﬂect variation in the proportion of
patients in each country using incontinence pads. CONCLU-
SION: In this model more than twice as many patients achieve
persistent control with TER than with OIR. The model estimated
the cost per patient achieving persistent control would be lower
with TER than with OIR.
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OBJECTIVES: Studies showed secondary prevention of cardio-
vascular (CV) events to be cost-effective, but only few reports
proved cost-effectiveness in primary prevention, in particular
with respect to nephrologic markers such as urinary albumin
excretion (UAE). Our objective was to conduct cost-effectiveness
analysis of screening for albuminuria in general population 
and subsequent ACE-inhibitor treatment to prevent CV-events.
METHODS: Data is derived from the PREVEND-IT (Prevention
REnal and Vascular ENdstage Disease Intervention Trial) and the
PREVEND observational-cohort study. The PREVEND-IT was
a randomised placebo-controlled trial to assess the effects of fos-
inopril 20mg on CV-events in 864 subjects with UAE 15–300
mg/24hr, blood pressure <160/100mmHg and plasma choles-
terol <8.0mmol/L. Evaluation of treatment was based on the
PREVEND-IT; the screening part was primarily based on the
observational data (PREVEND) gathered among trial partici-
pants and beyond. Cost-effectiveness was estimated for the
Dutch population. Cost-effectiveness was expressed in net costs
per life-year gained (LYG) with a 4% discounting rate and (sto-
chastic) sensitivity analysis. Bootstrapping analysis was used to
derive 95% CI for the cost-effectiveness ratio (CER) and thresh-
old probabilities. RESULTS: Patients treated with fosinopril
